Patents by Inventor Dominic Zichi

Dominic Zichi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8945830
    Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).
    Type: Grant
    Filed: August 20, 2010
    Date of Patent: February 3, 2015
    Assignee: SomaLogic, Inc.
    Inventors: James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
  • Publication number: 20140296102
    Abstract: A nucleic acid ligand “biochip” is disclosed, consisting of a solid support to which one or more specific nucleic acid ligands is attached in a spatially defined manner. Each nucleic acid ligand binds specifically and avidly to a particular target molecule contained within a test mixture, such as a bodily fluid. The target molecules include, but are not limited to, proteins (cellular, viral, bacterial, etc.) hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins. Contacting the test mixture with the biochip leads to the binding of a target molecule to its cognate nucleic acid ligand. The biochip may then be contacted with a reagent(s) that reacts covalently with proteins and not with nucleic acids. Each protein target in the test mixture may then detected by detecting the presence of the reagent at the appropriate address on the biochip.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Larry Gold, Dominic Zichi
  • Publication number: 20140249043
    Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The methods described create a nucleic acid surrogate for a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, especially protein targets. The disclosure further describes aptamer constructs that facilitate the use of aptamers in a variety of analytical detection applications.
    Type: Application
    Filed: February 10, 2014
    Publication date: September 4, 2014
    Applicant: SOMALOGIC, INC.
    Inventors: Daniel J. Schneider, Dan Nieuwlandt, Bruce Eaton, Martin Stanton, Shashi Gupta, Stephan Kraemer, Dominic Zichi, Larry Gold
  • Patent number: 8409795
    Abstract: The present disclosure describes improved SELEX methods for generating nucleic acid ligands that are capable of binding to target molecules and improved photoSELEX methods for generating photoreactive nucleic acid ligands that are capable of both binding and covalently crosslinking to target molecules. The disclosure further describes nucleic acid libraries having expanded physical and chemical properties and their use in SELEX and photoSELEX; methods for increasing the crosslinking efficiencies of photoaptamers; methods for producing photoaptamers having selective modifications that enhance functionality and minimize non-specific photoreactions; and methods for generating truncated nucleic acid ligands from nucleic acid ligands of longer length. The disclosure further describes aptamers and photoaptamers obtained by using any of the foregoing.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: April 2, 2013
    Assignee: Somalogic, Inc.
    Inventors: Daniel J. Schneider, Sheri K. Wilcox, Dominic Zichi, Dan Nieuwlandt, Jeff Carter, Larry Gold
  • Patent number: 8404830
    Abstract: The present disclosure is directed to the field of nucleic acid chemistry, specifically to 5-position modified uridines, as well as, oligonucleotides comprising said 5-position modified uridines. The present disclosure describes methods for producing aptamers comprising said 5-position modified uridines that are capable of binding to target molecules.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: March 26, 2013
    Assignee: SomaLogic, Inc.
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Patent number: 8293190
    Abstract: A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: October 23, 2012
    Assignees: Sumitomo Bakelite Company, Ltd., Somalogic, Inc.
    Inventors: Mitsutaka Matsumoto, Sumio Shibahara, Takayuki Matsumoto, Kanehisa Yokoyama, Sohei Funaoka, Daisuke Masuda, Michael Patrick Coleman, Dominic Zichi
  • Publication number: 20120165217
    Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer. In another aspect, methods are provided for diagnosing cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 24, wherein the individual is classified as having cancer, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.
    Type: Application
    Filed: April 3, 2010
    Publication date: June 28, 2012
    Applicant: SOMALOGIC, INC.
    Inventors: Larry Gold, Edward N. Brody, Rachel M. Ostroff, Dominic Zichi, Alex A.E. Stewart, Michael Riel-Mehan, Mark Messenbaugh, Randee S. Schwartz, Jeffery Walker, Stephen Alaric Williams, Malti Nikrad
  • Publication number: 20120143805
    Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer. In another aspect, methods are provided for diagnosing cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 47, wherein the individual is classified as having cancer, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.
    Type: Application
    Filed: March 5, 2010
    Publication date: June 7, 2012
    Applicant: SOMALOGIC, INC.
    Inventors: Larry Gold, Edward N. Brody, Rachel M. Ostroff, Dominic Zichi, Alex A.E. Stewart, Michael Riel-Mehan, Mark Messenbaugh, Randee S. Schwartz, Jeffery Walker, Stephen Alaric Williams, Malti Nikrad
  • Publication number: 20120115752
    Abstract: The present disclosure describes the identification and use of aptamers and photoaptamers having slower dissociation rate constants than those obtained using previously described methods. Specifically, the present disclosure describes methods for the identification and use of aptamers to one or more targets within a histological or cytological sample, which have slow rates of dissociation. The aptamers may be used to assess localization, relative density, and presence or absence of one or more targets in cytological and histological samples. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. The aptamers may also be used to introduce target specific signal moieties. In addition to target identification, the aptamers may be used to amplify signal generation through a variety of methods.
    Type: Application
    Filed: July 9, 2010
    Publication date: May 10, 2012
    Applicant: SOMALOGIC, INC.
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold, Thale C. Jarvis, Jeffrey D. Carter
  • Publication number: 20120070474
    Abstract: A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate.
    Type: Application
    Filed: November 29, 2011
    Publication date: March 22, 2012
    Applicants: SUMALOGIC, INC., SUMITOMO BAKELITE COMPANY, LTD.
    Inventors: Mitsutaka MATSUMOTO, Sumio SHIBAHARA, Takayuki MATSUMOTO, Kanehisa YOKOYAMA, Sohei FUNAOKA, Daisuke MASUDA, Michael Patrick COLEMAN, Dominic ZICHI
  • Patent number: 8088340
    Abstract: A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate.
    Type: Grant
    Filed: March 14, 2006
    Date of Patent: January 3, 2012
    Assignees: Sumitomo Bakelite Company, Ltd., Somalogic, Inc.
    Inventors: Mitsutaka Matsumoto, Sumio Shibahara, Takayuki Matsumoto, Kanehisa Yokoyama, Sohei Funaoka, Daisuke Masuda, Michael Patrick Coleman, Dominic Zichi
  • Patent number: 8071288
    Abstract: The present invention provides novel methods and reagents for detecting the binding of protein targets to nucleic acid ligands. Using Universal Protein Stains (UPS), proteins bound by nucleic acid ligands may be labeled with a detectable moiety. The methods and reagents are particularly useful for the detection of protein targets bound to multiplexed arrays of nucleic acid ligands. The present invention also provides novel methods for the multiplexed evaluation of photocrosslinking nucleic acid ligands. The methods allow one simultaneously to: (1) evaluate the performance (dynamic range) of a plurality of photocrosslinking nucleic acid ligands; and (2) assess the specificity of each photocrosslinking nucleic acid ligand for its cognate target protein. Photocrosslinking nucleic acid ligands with the most desirable properties can then be selected for use in diagnostic and prognostic medical assays.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: December 6, 2011
    Assignee: SomaLogic, Inc.
    Inventors: Larry Gold, Jonathan Drew Smith, Dominic Zichi, Daniel J. Schneider, Chad Greef
  • Publication number: 20110245479
    Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.
    Type: Application
    Filed: May 23, 2011
    Publication date: October 6, 2011
    Applicant: SOMALOGIC, INC.
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Patent number: 7964356
    Abstract: The present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. This invention relates to the field of diagnostic histology, cytology, histopathology, and cytopathology methods and reagents for the detection of various disease states. More specifically, the invention relates to the use of aptamers in histologic, cytologic, histopathic, and/or cytopathic diagnostic methods. Aptamers may be provided that react with specific target molecules contained within a histological or cytological sample. Aptamers may be used to assess localization, relative density, and presence or absence of one or more target. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: June 21, 2011
    Assignee: SomaLogic, Inc.
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Publication number: 20110136099
    Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The methods described create a nucleic acid surrogate for a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, especially protein targets. The disclosure further describes aptamer constructs that facilitate the use of aptamers in a variety of analytical detection applications.
    Type: Application
    Filed: December 2, 2010
    Publication date: June 9, 2011
    Applicant: SOMALOGIC, INC.
    Inventors: Daniel J. Schneider, Dan Nieuwlandt, Bruce Eaton, Marty Stanton, Shashi Gupta, Stephan Kraemer, Dominic Zichi, Larry Gold
  • Patent number: 7947447
    Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: May 24, 2011
    Assignee: SomaLogic, Inc.
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Publication number: 20110082286
    Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.
    Type: Application
    Filed: December 15, 2010
    Publication date: April 7, 2011
    Applicant: SOMALOGIC, INC.
    Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
  • Patent number: 7855054
    Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The methods described create a nucleic acid surrogate for a non nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, especially protein targets. The disclosure further describes aptamer constructs that facilitate the use of aptamers in a variety of analytical detection applications.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: December 21, 2010
    Assignee: SomaLogic, Inc.
    Inventors: Daniel J. Schneider, Dan Nieuwlandt, Bruce Eaton, Marty Stanton, Shashi Gupta, Stephan Kraemer, Dominic Zichi, Larry Gold
  • Publication number: 20100317120
    Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).
    Type: Application
    Filed: August 20, 2010
    Publication date: December 16, 2010
    Applicant: SOMALOGIC, INC.
    Inventors: James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
  • Publication number: 20100221752
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of ovarian cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose ovarian cancer or permit the differential diagnosis of a pelvic mass as benign or malignant. In another aspect, methods are provided for diagnosing ovarian cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having ovarian cancer, or the likelihood of the individual having ovarian cancer is determined, based on the at least one biomarker value.
    Type: Application
    Filed: October 6, 2009
    Publication date: September 2, 2010
    Applicant: SomaLogic, Inc.
    Inventors: Larry Gold, Marty Stanton, Edward Brody, Rachel Ostroff, Dominic Zichi, Alex Stewart